Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thyroid Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1

Interventions

Oncolytic Virotherapy 4Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Tobacco Use Cessation Devices 2Positron-Emission Tomography 2perflutren 1pembrolizumab 1osimertinib 1icotinib 1gallium 68 PSMA-11 1dapagliflozin 1dacomitinib 1clevudine 1aldesleukin 1Vitamin A 1Tomography, Emission-Computed, Single-Photon 1Tetrahydrouridine 1Technetium 1Sulfur Hexafluoride 1Sufentanil 1Standard of Care 1Specimen Handling 1Ropivacaine 1Radiotherapy 1Radiosurgery 1Probiotics 1Practice Guidelines as Topic 1Positron Emission Tomography Computed Tomography 1Pentetic Acid 1Nicotine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lung Neoplasms × Probiotics × Clear all
NCT04857697 2023-04-21

Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer

Mayo Clinic

Phase EARLY_PHASE1 Completed
6 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡